Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

"Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a treatment that evaluates the effectiveness and the safety of oral BIBF 1120 in combination with standard docetaxel therapy, which can be administered (at the discretion of the referring physician) with tri-weekly or weekly schedule

Trial Profile

"Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a treatment that evaluates the effectiveness and the safety of oral BIBF 1120 in combination with standard docetaxel therapy, which can be administered (at the discretion of the referring physician) with tri-weekly or weekly schedule

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SENECA
  • Most Recent Events

    • 10 Sep 2019 Status changed to active, no longer recruiting as per results presented at the 20th World Conference on Lung Cancer
    • 10 Sep 2019 Results evaluating 16 patients previously treated with immunotherapy and comparing them to the rest of patient population presented at the 20th World Conference on Lung Cancer
    • 26 Sep 2018 Results (From January 2016 to data cut-off, on 30th March 2018, n= 197) presented at the 19th World Conference on Lung Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top